Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 16,980 |
|
|||||
| News | - | ||||||
| Day High | 11.93 | Low High |
|||||
| Day Low | 11.39 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Pieris Pharmaceuticals Inc | PIRS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.12 | 1.03% | 11.72 | 18:42:50 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.50 | 11.39 | 11.93 | 11.72 | 11.60 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,457 | 16,980 | US$ 11.71 | US$ 198,849 | - | 10.888 - 80.80 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:54:59 | 1 | US$ 11.39 | USD |
Pieris Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.16B | 98.85M | - | 42.81M | -24.54M | -0.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Pieris Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/14/2024 | 15:37 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/14/2024 | 12:12 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/14/2024 | 08:19 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/02/2024 | 08:59 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 12/21/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2023 | 15:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/31/2023 | 15:15 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
| 8/10/2023 | 16:04 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 8/10/2023 | 15:24 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/18/2023 | 08:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/13/2023 | 06:30 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PIRS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.32 | 12.93 | 11.04 | 11.66 | 800,229 | -0.60 | -4.87% |
| 1 Month | 15.20 | 15.20 | 11.04 | 12.88 | 518,949 | -3.48 | -22.89% |
| 3 Months | 14.392 | 22.32 | 11.04 | 14.68 | 681,462 | -2.67 | -18.57% |
| 6 Months | 19.168 | 23.20 | 10.888 | 14.79 | 580,095 | -7.45 | -38.86% |
| 1 Year | 64.216 | 80.80 | 10.888 | 25.08 | 1,440,296 | -52.50 | -81.75% |
| 3 Years | 182.40 | 492.00 | 10.888 | 214.22 | 1,710,850 | -170.68 | -93.57% |
| 5 Years | 235.20 | 496.00 | 10.888 | 223.29 | 1,220,697 | -223.48 | -95.02% |
Pieris Pharmaceuticals Description
| Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States. |
